# EDGAR Filing Document

**Accession Number:** 0001488039
**File Stem:** 0001193125-26-061342
**Filing Date:** 2026-2
**Character Count:** 2511
**Document Hash:** 21eac3901fc55b30d51b7b9dd6cf3c52
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-061342.hdr.sgml**: 20260220

**ACCESSION NUMBER**: 0001193125-26-061342

**CONFORMED SUBMISSION TYPE**: 424B3

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260220

**DATE AS OF CHANGE**: 20260220

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ATOSSA THERAPEUTICS, INC.
- **CENTRAL INDEX KEY:** 0001488039
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 264753208
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 424B3
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-279367
- **FILM NUMBER:** 26659874

**BUSINESS ADDRESS:**
- **STREET 1:** 1448 NW MARKET STREET
- **STREET 2:** SUITE 500
- **CITY:** SEATTLE
- **STATE:** WA
- **ZIP:** 98107
- **BUSINESS PHONE:** 206.588.0256

**MAIL ADDRESS:**
- **STREET 1:** 1448 NW MARKET STREET
- **STREET 2:** SUITE 500
- **CITY:** SEATTLE
- **STATE:** WA
- **ZIP:** 98107

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ATOSSA GENETICS INC
- **DATE OF NAME CHANGE:** 20100325

**Filed Pursuant to Rule 424(b)(3)** 

**Registration No. 333-279367** 

**Prospectus Supplement** 

**(To Prospectus dated May 23, 2024)**![LOGO](g86661g0220124658210.jpg)

This prospectus supplement supplements and amends the prospectus dated May 23, 2024 (the "Prospectus"), as supplemented and amended by that certain prospectus supplement dated November 19, 2024 covering the offering, issuance and sale of up to a maximum aggregate offering price of $100,000,000 (the "Maximum Offering Price") of our common stock that may be issued and sold under an Open Market Sale Agreement<sup>SM</sup> with Jefferies LLC (the "ATM Facility").

Effective as of February 20, 2026, we have reduced the Maximum Offering Price to $0. As of the date of this prospectus supplement, no shares have been sold under the ATM Facility.

You should read this prospectus supplement, together with additional information described under the headings "Information Incorporated by Reference" and "Where You Can Find Additional Information" in the Prospectus carefully before you invest in our securities.

Investing in our securities involves a high degree of risk. Before making any investment in our securities, you should consider carefully the risks and uncertainties described in the section entitled "Risk Factors" beginning on page 7 of the Prospectus.

The date of this prospectus supplement is February 20, 2026.